Blog

- Andrew Celentano

Instylla Gains U.S. FDA Premarket Approval for Embrace™ Hydrogel Embolic System

BEDFORD, Mass., Aug. 7, 2025 /PRNewswire/ — Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, announced premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for the company’s flagship product Embrace™ Hydrogel Embolic System. Embrace HES has been approved for the embolization of hypervascular tumors in peripheral arteries ≤ 5mm.

Read More »

Virtual reality shows promise in easing stress for cardiac patients

Living with cardiovascular disease often takes a serious emotional toll—and with stress known to worsen heart health, there’s growing interest in low-risk, innovative ways to help patients cope. New research from UCLA Health suggests that virtual reality (VR) may offer a promising tool to ease psychological stress and support heart health.

Read More »